ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Diagnostic performance of urinary adipsin as a screening biomarker for pre-eclampsia.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated the diagnostic performance of urinary adipsin as a potential biomarker for pre-eclampsia screening in a low-resource setting.
methodsA case-control study was conducted involving 150 pregnant women classified into three groups: 50 healthy pregnancies, 50 high-risk pregnancies without pre-eclampsia, and 50 pregnant women clinically diagnosed with pre-eclampsia. Urinary adipsin concentration was measured with a commercial sandwich ELISA kit. Linear regression was conducted to examine the relationship between urinary adipsin levels and pre-eclampsia risk, while receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance of urinary adipsin.
resultsUrinary adipsin levels were significantly higher in pre-eclamptic women compared to healthy controls and the high-risk group (1258.70 ± 342.88 ng/mg Cr vs. 284.16 ± 24.04 ng/mg Cr and 305.15 ± 36.10 ng/mg Cr; P < 0.001). At a cutoff value of 750 ng/mg Cr, urinary adipsin demonstrated a good diagnostic performance, with a sensitivity of 83.6% and a specificity of 88.9%. Combining urinary adipsin with blood pressure measurements significantly improved the predictive performance (P < 0.001), with 96.7% sensitivity, 91.0% specificity, and an area under the curve (AUC) of 0.930. The combination of urinary adipsin, urine protein-to-creatinine ratio (uPCR), and blood pressure measurement further enhanced specificity (99.7%) with a sensitivity of 90.5% (AUC = 0.909).
conclusionUrinary adipsin showed high sensitivity, specificity, and predictive value in diagnosing pre-eclampsia. This highlights its potential as a non-invasive biomarker for pre-eclampsia screening in low-resource settings. Routine urinary adipsin assay and blood pressure monitoring could enhance early detection strategies and improve maternal and perinatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.